Allicin alleviates inflammation of trinitrobenzenesulfonic acid-induced rats and suppresses P38 and JNK pathways in Caco-2 cells

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Li, Chen ^a   Lun, Weijian ^a   Zhao, Xinmei ^a   Lei, Shan ^a   Guo, Yandong ^a   Ma, Jiayi ^a   Zhi, Fachao ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 8; MESALAZINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SALAZOSULFAPYRIDINE; STRESS ACTIVATED PROTEIN KINASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; SULFINIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CACO 2 CELL LINE; COLITIS; COLON; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; NONHUMAN; NONPARAMETRIC TEST; PARAMETRIC TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WEIGHT REDUCTION; ANIMAL; CACO-2 CELL LINE; DRUG EFFECTS; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION;

RATTUS;

ANIMALS; CACO-2 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MESALAMINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; SIGNAL TRANSDUCTION; SULFASALAZINE; SULFINIC ACIDS; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924077673     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/434692     Document Type: Article

References (36)

1. N. A. Molodecky, I. S. Soon, D. M. Rabi et al., "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review," Gastroenterology, vol. 142, no. 1, pp. 46.e42-54.e42, 2012.
2. O. J. Adedokun,W. J. Sandborn, B. G. Feagan et al., "Association between serumconcentration of infliximab and efficacy in adult patients with ulcerative colitis," Gastroenterology, vol. 147, no. 6, pp. 1296-1307, 2014.
3. S. Karoui, N. Bibani, I. B. Gorbel et al., "Leukocytoclastic vasculitis: a rare adverse effect secondary to infliximab," Inflammatory Bowel Diseases, vol. 17, no. 2, pp. E4-E5, 2011.
4. M. Iborra, B. Beltrán, G. Bastida,M. Aguas, and P. Nos, "Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect," Journal of Crohn's and Colitis, vol. 5, no. 2, pp. 157-161, 2011.
5. A. A. Powolny and S. V. Singh, "Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds," Cancer Letters, vol. 269, no. 2, pp. 305-314, 2008.
6. D. H. Alpers, "Garlic and its potential for prevention of colorectal cancer and other conditions," Current Opinion in Gastroenterology, vol. 25, no. 2, pp. 116-121, 2009.
7. Y. Zhou, W. Zhuang, W. Hu, G. Liu, T. Wu, and X. Wu, "Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in ameta-analysis," Gastroenterology, vol. 141, no. 1, pp. 80-89, 2011.
8. W. Zhang,M. Ha,Y. Gong, Y. Xu,N. Dong, and Y. Yuan, "Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways," Oncology Reports, vol. 24, no. 6, pp. 1585-1592, 2010.
9. C. J. Cavallito and J. H. Bailey, "Allicin, the antibacterial principle of Allium sativum. I. Isolation, physical properties and antibacterial action," Journal of the American Chemical Society, vol. 66, no. 11, pp. 1950-1951, 1944.
10. N. Li, R. Guo, W. Li et al., "A proteomic investigation into a human gastric cancer cell line BGC823 treated with diallyl trisulfide," Carcinogenesis, vol. 27, no. 6, pp. 1222-1231, 2006.
11. J. O. Ban, D. Y. Yuk, K. S. Woo et al., "Inhibition of cell growth and induction of apoptosis via inactivation of NF-κB by a sulfurcompound isolated from garlic in human colon cancer cells," Journal of Pharmacological Sciences, vol. 104, no. 4, pp. 374-383, 2007.
12. T. Jess, E. V. Loftus Jr., F. S. velayos et al., "Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen County, Denmark and Olmsted County, Minnesota," The American Journal of Gastroenterology, vol. 102, no. 4, pp. 829-836, 2007.
13. T. L. Zisman and D. T. Rubin, "Colorectal cancer and dysplasia in inflammatory bowel disease,"World Journal of Gastroenterology, vol. 14, no. 17, pp. 2662-2669, 2008.
14. J. Yamashita,C. Iwamura, T. Ito et al., "Paraoxonase-1 suppresses experimental colitis via the inhibition of IFN-γ production from CD4 T cells," The Journal of Immunology, vol. 191, no. 2, pp. 949-960, 2013.
15. P. Biancheri, A. Di Sabatino, F. Ammoscato et al., "Absence of a role for interleukin-13 in inflammatory bowel disease," European Journal of Immunology, vol. 44, no. 2, pp. 370-385, 2014.
16. C. O. Elson, K. W. Beagley, A. T. Sharmanov et al., "Hapteninduced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance," Journal of Immunology, vol. 157, no. 5, pp. 2174-2185, 1996.
17. G. P. Morris, P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk, and J. L. Wallace, "Hapten-induced model of chronic inflammation and ulceration in the rat colon," Gastroenterology, vol. 96, no. 3, pp. 795-803, 1989.
18. S. Wirtz, C. Neufert, B. Weigmann, and M. F. Neurath, "Chemically induced mousemodels of intestinal inflammation," Nature Protocols, vol. 2, no. 3, pp. 541-546, 2007.
19. M. F. Neurath, "Cytokines in inflammatory bowel disease," Nature Reviews Immunology, vol. 14, no. 5, pp. 329-342, 2014.
20. C. Garlanda, C. A. Dinarello, and A. Mantovani, "The interleukin- 1 family: back to the future," Immunity, vol. 39, no. 6, pp. 1003-1018, 2013.
21. M. G. Netea, F. L. van de veerdonk, J. W. M. van der Meer, C. A. Dinarello, and L. A. B. Joosten, "Inflammasome-independent regulation of IL-1-family cytokines," Annual Review of Immunology, vol. 1, pp. 3.1-3.29, 2014.
22. Y. Karrout, L. Dubuquoy, C. Piveteau et al., "In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy," Journal of Controlled Release, vol. 197, pp. 121-130, 2015.
23. G. Rogler and T. Andus, "Cytokines in inflammatory bowel disease," World Journal of Surgery, vol. 22, no. 4, pp. 382-389, 1998.
24. M.-C. Li and S.-H. He, "IL-10 and its related cytokines for treatment of inflammatory bowel disease," World Journal of Gastroenterology, vol. 10, no. 5, pp. 620-625, 2004.
25. B. Romier, J. van de Walle, A. During, Y. Larondelle, and Y.-J. Schneider, "Modulation of signalling nuclear factor-κB activation pathway by polyphenols in human intestinal Caco- 2 cells," British Journal of Nutrition, vol. 100, no. 3, pp. 542-551, 2008.
26. R. Daig, T. Andus, E. Aschenbrenner, W. Falk, J. Schölmerich, and V. Gross, "Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease," Gut, vol. 38, no. 2, pp. 216-222, 1996.
27. L. Mazzucchelli, C. Hauser, K. Zgraggen et al., "Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation," The American Journal of Pathology, vol. 144, no. 5, pp. 997-1007, 1994.
28. M. S. Hayden and S. Ghosh, "Shared principles in NF-κB signaling," Cell, vol. 132, no. 3, pp. 344-362, 2008.
29. E. G. Maiorov, O. Keskin, A. Gursoy, and R. Nussinov, "The structural network of inflammation and cancer: merits and challenges," Seminars in Cancer Biology, vol. 23, no. 4, pp. 243-251, 2013.
30. D. L. Boone, E. G. Lee, S. Libby et al., "Recent advances in understanding: NF-κB regulation," Inflammatory Bowel Diseases, vol. 8, no. 3, pp. 201-212, 2002.
31. M. Qi and E. A. Elion, "MAP kinase pathways," Journal of Cell Science, vol. 118, no. 16, pp. 3569-3572, 2005.
32. J. Epstein, G. Docena, T. T. MacDonald, and I. R. Sanderson, "Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1β and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease," British Journal of Nutrition, vol. 103, no. 6, pp. 824-832, 2010.
33. G. L. Johnson and R. Lapadat, "Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases," Science, vol. 298, no. 5600, pp. 1911-1912, 2002.
34. C. Dong, R. J. Davis, and R. A. Flavell, "MAP kinases in the immune response," Annual Review of Immunology, vol. 20, pp. 55-72, 2002.
35. L. M. Knowles and J. A. Milner, "Diallyl disulfide induces ERK phosphorylation and alters gene expression profiles in human colon tumor cells," Journal of Nutrition, vol. 133, no. 9, pp. 2901-2906, 2003.
36. L. M. Knowles and J. A. Milner, "Depressed p34cdc2 kinase activity and G2/M phase arrest induced by diallyl disulfide in HCT-15 cells," Nutrition and Cancer, vol. 30, no. 3, pp. 169-174, 1998.